Viz Revenue, Valuation, Funding & Investors

Viz is valued at $1.3B as of March 2023, a 12.8x multiple on its last reported $100M revenue.

See full Viz profile

Last Viz valuation

$1.3B

Undisclosed stage · Mar 2023

Last Viz funding round

$40M

Undisclosed stage · Mar 2023

Viz revenue

$100M

Undisclosed stage · Mar 2023

Key investors in Viz

  • Pear VC
  • Kleiner Perkins
  • GV
  • CRV
  • Susa Ventures
  • Innovation Endeavors

Viz Overview

About Viz

Viz.ai is a San Francisco-based artificial intelligence company that develops a care-coordination platform for hospitals, using machine learning to analyze medical imaging such as CT scans and alert care teams to time-sensitive conditions. Originally focused on stroke detection, the platform has expanded to other conditions including pulmonary embolism and aortic disease, with FDA clearances and Medicare reimbursement supporting adoption. Viz.ai is deployed across more than 1,300 hospitals, connecting radiologists, emergency physicians, and specialists to speed diagnosis and treatment decisions.


Founded

2016

HQ

United StatesUnited States

Website

viz.ai

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Revenue

$100M (Mar 2023)

Valuation

$1.3B (Mar 2023)

Viz Valuation

Viz is currently valued at $1.3B, based on its undisclosed-stage round in March 2023.

The $40M round was led by CIBC Innovation Banking.

Viz's valuation has grown 1.1x from $1.2B at its Series D in April 2022 to $1.3B in March 2023, across 2 priced rounds.

Viz valuation by funding round

Revenue multiple
Viz valuation by funding round
DateStageValuationRevenue Multiple
Mar 2023Undisclosed stage$1.3B12.8x
Apr 2022Series D$1.2B52.2x

Viz Revenue

Viz's latest recorded revenue is $100M, as of its undisclosed-stage round in March 2023. At a $1.3B valuation, that implies a 12.8x revenue multiple.

Revenue grew from $23M in April 2022 to $100M in March 2023, while the revenue multiple moved from 52.2x to 12.8x.

Viz revenue by funding round

Viz revenue and valuation multiple by funding round
DateRevenue *ValuationRevenue MultipleStage
Mar 2023$100M$1.3B12.8xUndisclosed stage
Apr 2022$23M$1.2B52.2xSeries D

* Revenue (or ARR) figures are the values recorded alongside each funding round. Typically run-rate revenue at the time of the deal, or a reported LTM (last 12 months) revenue.

Viz Funding History

Viz has raised a total of $292M across 7 funding rounds.

Viz's first fundraising round was a $2M seed round in October 2016. The most recent completed round was a $40M undisclosed-stage round in March 2023.

Viz funding rounds

Viz funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Mar 2023Undisclosed stageCIBC Innovation Banking (lead)$40M$1.3BViz.ai is a San Francisco-based artificial intelligence platform that uses machine learning to expedite disease detection, inform critical care decisions, and optimize care pathways across healthcare systems. The platform connects and activates entire care teams including radiologists, emergency physicians, and specialists to improve patient outcomes and increase access to life-saving treatments. As of March 2023, Viz.ai was operational across more than 1,300 hospitals, serving a patient every 21 seconds. In March 2023, Viz.ai completed a Series D funding round in which CIBC Innovation Banking provided $40 million in growth capital financing. The round valued the company at $1.28 billion post-money. The funding was designated to expand the AI-powered care coordination platform, explore strategic acquisition opportunities, and extend the platform into new disease areas. Additional investors in the Series D round included Insight Partners, Tiger Global, Kleiner Perkins, Google Ventures, Scale Venture Partners, and Greenoaks Capital Partners, reflecting strong institutional backing from leading venture firms.
Apr 2022Series DInsight Partners (lead); Tiger Global (lead); Sozo Ventures; Susa Ventures; Kleiner Perkins; Pear VC; GV; Scale Venture Partners; Threshold; CRV$100M$1.2BViz.ai is an AI-powered healthcare software company specializing in disease detection and intelligent care coordination for hospitals. The company operates a subscription-based model deployed across U.S. health systems and has expanded into life sciences partnerships with pharmaceutical and medical device companies. In April 2022, Viz.ai closed a Series D funding round at a $1.2 billion post-money valuation, achieving unicorn status. The round was led by Tiger Global and other prominent investors including Google Ventures, Kleiner Perkins, and others, bringing total funding to approximately $289 million across 10 rounds by 2023. Based on available estimates, Viz.ai generated approximately $23 million in revenue in 2022, growing to roughly $40 million in 2023 (approximately 100% year-over-year growth). The company reported annual recurring revenue (ARR) of $12 million in 2020, with expectations to reach $100 million by 2024 as adoption accelerated. By early 2024, Viz.ai had expanded its hospital footprint to over 1,500 U.S. institutions serving approximately 45,000 healthcare providers, and by late 2025 had grown to nearly 2,000 hospitals covering 230 million lives, with the company achieving profitability in its healthcare business during 2025.
Mar 2021Series CInsight Partners (lead); Scale Venture Partners (lead); Greenoaks; Susa Ventures; Kleiner Perkins; Pear VC; Innovation Endeavors; Threshold; CRV$71M-Viz.ai develops an AI-powered care coordination platform primarily for stroke detection and treatment, using algorithms to analyze medical imaging like CT scans and alert care teams via mobile apps for faster response times. The platform has expanded to other conditions like pulmonary embolism and aortic disease, with FDA approvals and Medicare reimbursement, and is deployed in nearly 2,000 U.S. hospitals covering over 230 million lives as of late 2025. It generates revenue through a subscription model charging hospitals based on algorithms used and population served, with ARR reaching $12 million in 2020 and projected to hit $100 million by 2024. In the specified March 2021 funding round, Viz.ai raised approximately $71 million co-led by Insight Partners and Scale Venture Partners, with participation from CRV, Greenoaks, Innovation Endeavors, Kleiner Perkins, Pear VC, Susa Ventures, and Threshold, among others. This round contributed to total funding exceeding $289 million across 10 rounds by 2023 from investors including Tiger Global and Google Ventures. Near the 2021 round date, Viz.ai's ARR stood at $12 million in 2020, roughly doubling annually, with actual accounting revenue lower due to subscription recognition. The company achieved rapid adoption, signing contracts covering two-thirds of the U.S. population by 2021, and expanded into life sciences partnerships, reaching 13 by late 2025 including major pharmaceutical firms for clinical trials. Viz.ai competes in the medical AI space, focusing on regulated healthcare workflows with real-world evidence of reduced diagnosis times and improved outcomes. It reported healthcare business profitability in 2025, with estimated revenue growing to $40 million in 2023 and $65 million projected for 2024. Strategic expansions included new use cases on the Viz.ai One platform and growth to 60,000 healthcare providers by 2024.
Oct 2019Series BGreenoaks (lead); Kleiner Perkins; Pear VC; GV; Threshold; CRV$50M-Viz.ai is a Tel Aviv and San Francisco-based healthcare AI company that developed synchronized clinical decision support software for stroke detection. The company's flagship product, Viz LVO, uses deep learning to automatically scan CT images of the brain and alerts stroke specialists to suspected large vessel occlusions, enabling rapid treatment. Viz.ai received FDA De Novo clearance in February 2018 and achieved significant clinical adoption, expanding from a few research institutes to over 300 US hospitals by October 2019. In October 2019, Viz.ai announced a $50 million Series B funding round led by Greenoaks, with participation from Threshold Ventures, CRV, and existing investors GV (Google Ventures) and Kleiner Perkins. This round brought the company's total funding to over $78 million. The company used the capital to expand its technology to additional disease states and geographic markets, building on strong adoption driven by demonstrated time savings that directly improved patient outcomes in acute stroke care. Viz.ai had also secured a major distribution partnership with Medtronic in July 2019, positioning the company for expanded reach in US treatment centers.
Jul 2018Series AKleiner Perkins (lead); Pear VC; GV; DHVC$21M-Viz.ai is an AI healthcare startup founded in 2016 in San Francisco, developing software to detect early signs of time-sensitive medical conditions like strokes through analysis of brain scans such as CT scans for large vessel occlusions (LVOs). The platform uses deep learning to identify stroke indicators and alert neurological specialists within minutes, fitting into existing emergency room workflows without disruption, and received FDA clearance in February 2018. The company raised $21 million in a Series A round on July 18, 2018, led by Kleiner Perkins with participation from GV (Alphabet's venture capital arm), following a prior $10 million in funding. The new funding was intended to support expansion into new markets and broaden the technology's scope beyond strokes. Kleiner Perkins General Partner Mamoon Hamid joined Viz.ai's board, highlighting the platform's physician-driven adoption model. Viz.ai positioned itself to make healthcare proactive, increasing access to life-saving therapies and reducing treatment times. Later rounds included a $50 million Series B in 2019 led by Greenoaks with participation from Threshold Ventures, CRV, GV, and Kleiner Perkins, and a $100 million Series D in April 2022 at $1.2 billion valuation led by Tiger Global and Insight Partners.
May 2017SeedDHVC (lead); Innovation Endeavors (lead); Pear VC; AME Cloud Ventures$8M-Viz.ai is a San Francisco-based AI-driven medical imaging company founded in 2016, initially focused on stroke detection to enable faster treatment through intelligent care coordination. In May 2017, the year-old startup raised $7.5 million in a seed round co-led by DHVC and Innovation Endeavors, with participation from AME Cloud Ventures and Pear VC. The funding supported development of its AI platform for time-sensitive image analysis in acute care scenarios. The seed round brought early validation from prominent investors including Jerry Yang’s AME Cloud Ventures. Viz.ai aimed to apply artificial intelligence to medical imaging, addressing critical needs in stroke care by reducing notification times, as later validated in studies showing median times under six minutes. Subsequent rounds included a $71 million Series C in March 2021 led by Scale Venture Partners and Insight Partners, bringing total funding over $150 million at that point, with expansion into cardiology, pulmonary, and trauma care.
Oct 2016SeedSusa Ventures; Pear VC; Techammer; Innovation Endeavors; AME Cloud Ventures; Seedcamp; DHVC$2M--

Who has invested in Viz?

17 investors have backed Viz across its funding rounds, including Pear VC, Kleiner Perkins, GV, CRV, Susa Ventures and Innovation Endeavors.

Lead investors include CIBC Innovation Banking, Insight Partners, Tiger Global, Scale Venture Partners, Greenoaks and 3 other investors.


Viz Investors

Investors in Viz by funding rounds participated
InvestorHQRoundsRoleFirst check
Pear VCUnited StatesSan Francisco, CA6ParticipantOct 2016
Kleiner PerkinsUnited StatesSan Francisco, CA4LeadJul 2018
Susa VenturesUnited StatesSan Francisco, CA3ParticipantOct 2016
GVUnited StatesSan Francisco, CA3ParticipantJul 2018
Innovation EndeavorsUnited StatesSan Francisco, CA3LeadOct 2016
DHVCUnited StatesSan Francisco, CA3LeadOct 2016
ThresholdUnited StatesSan Francisco, CA3ParticipantOct 2019
CRVUnited StatesUnited States3ParticipantOct 2019
GreenoaksUnited StatesSan Francisco, CA2LeadOct 2019
Scale Venture PartnersUnited StatesSan Francisco, CA2LeadMar 2021
AME Cloud VenturesUnited StatesSan Francisco, CA2ParticipantOct 2016
Insight PartnersUnited StatesNew York City, NY2LeadMar 2021
Sozo VenturesUnited StatesSan Francisco, CA1ParticipantApr 2022

This data is available for Pro users. Sign up to see all 17 Viz investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Viz Competitors

Viz competitors include listed companies like RaySearch Labs, Lunit, United Imaging and Pro Medicus, and private ones like United Imaging Intelligence and MasterControl.

Public and private companies comparable to Viz
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
United Imaging IntelligenceChinaShanghaiPrivate--$1.4B-
RaySearch LabsSwedenSwedenPublicly listed$137M$59M$583M4.2x
LunitSouth KoreaSouth KoreaPublicly listed$61M($9M)$450M6.4x
United ImagingChinaChinaPublicly listed$2.1B$367M$12B4.8x
Pro MedicusAustraliaAustraliaPublicly listed$186M$147M$13B62.7x
MasterControlUnited StatesSalt Lake City, UTPrivate$100M-$1.3B13.0x
Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Sinocare$695M$43M1.9x1.8x31.0x15.3x
U.S. Physical Therapy$781M$110M2.5x2.3x17.5x18.9x
EverCommerce$589M$128M3.0x2.9x13.7x9.5x
SonoScape$344M$35M3.1x2.8x30.1x24.4x
Ramsay Santé$6.2B$720M0.9x-8.0x-
Castle Biosciences$344M($429K)2.6x2.5x(2082.6x)44.9x
Lumexa Imaging$1B$142M2.0x1.9x14.2x8.5x
Innovita Biological Tech$63M$27M13.4x13.6x31.3x35.5x

This data is available for Pro users. Sign up to see all Viz competitors and their valuation data.

Start Free Trial

Common questions about Viz

When was Viz founded?Viz was founded in 2016.
Where is Viz headquartered?Viz is headquartered in United States.
Is Viz publicly listed?No, Viz is a private, VC-backed company.
What is Viz's valuation?Viz was last valued at $1.3B in its undisclosed-stage round in March 2023.
How much funding has Viz raised?Viz has raised $292M across 7 funding rounds.
What was Viz's last funding round?Viz's last funding round was a $40M undisclosed-stage round in March 2023, led by CIBC Innovation Banking.
Who are Viz's investors?Viz's investors include Pear VC, Kleiner Perkins, Susa Ventures, GV, Innovation Endeavors, DHVC, Threshold, CRV, Greenoaks, Scale Venture Partners and 7 others.
What is Viz's revenue?Viz's latest recorded revenue is $100M (March 2023).
What is Viz's revenue multiple?Viz's latest valuation implies a 12.8x revenue multiple ($1.3B valuation on $100M of revenue).
Which companies are comparable to Viz?Companies comparable to Viz include United Imaging Intelligence, RaySearch Labs, Lunit, United Imaging, Pro Medicus and MasterControl.

See companies similar to Viz

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial